PLAC1 is a suitable candidate for cancer immunotherapy, since it is overexpressed in more than 80% of breast cancers samples, while overexpression of Her2/neu, the target of Herceptin monoclonal antibody, is utmost 25%[8,33]. Here, PLAC1 is linked to cancer.